Go to
current issue
-
Phase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Dan P. Zandberg, Jacob B. Allred, Ari J. Rosenberg, John M. Kaczmar, Paul Swiecicki, Ricklie A. Julian, Andrew S. Poklepovic, Jessica R. Bauman, Minh D. Phan, Nabil F. Saba, Edgardo Rivera, Kendrith Rowland, Diwakar Davar, Julia Cordes, Alan L. Ho, Miao Zhang, Stephanie A. Berg, Pamela N. Munster, Gary K. SchwartzJournal of Clinical Oncology, Ahead of Print.
-
Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Journal of Clinical Oncology, Ahead of Print.
-
Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/TP53 Mutation: SEQUOIA Arm D Results J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Mazyar Shadman, Talha Munir, Shuo Ma, Masa Lasica, Monica Tani, Tadeusz Robak, Ian W. Flinn, Jennifer R. Brown, Paolo Ghia, Emmanuelle Ferrant, Constantine S. Tam, Wojciech Janowski, Wojciech Jurczak, Linlin Xu, Tian Tian, Marcus Lefebure, Stephanie Agresti, Jamie Hirata, Alessandra TedeschiJournal of Clinical Oncology, Ahead of Print.
-
Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Journal of Clinical Oncology, Ahead of Print.
-
Use of Low-Value Cancer Treatments in Medicare Advantage Versus Traditional Medicare J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Jeah Jung, Caroline Carlin, Roger Feldman, Ge Song, Aaron MitchellJournal of Clinical Oncology, Ahead of Print.
-
Survival Benefit of Palliative Oophorectomy for Patients With Ovarian Metastasis From Baseline Metastatic Gastric Adenocarcinoma J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Matheus Sewastjanow-Silva, Lianchun Xiao, Ahmed Abdelhakeem, Cindy M. Pabon, Kohei Yamashita, Katsuhiro Yoshimura, Brian D. Badgwell, Naruhiko Ikoma, Larissa Meyer, Tara Sagebiel, Prajnan Das, Jenny J. Li, Jaffer A. Ajani, Mariela A. Blum-MurphyJournal of Clinical Oncology, Ahead of Print.
-
Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non–Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Journal of Clinical Oncology, Ahead of Print.
-
BMT-CARE App: A Randomized Controlled Trial of a Psychosocial Digital Application for Caregivers of Patients Undergoing Hematopoietic Stem-Cell Transplantation J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Jamie M. Jacobs, Lara Traeger, Madison Freese, Anna Barata, Richard Newcomb, Dustin Rabideau, Nora Horick, Zachariah DeFilipp, Yi-Bin Chen, Tamryn Gray, Julia Pepper, Ella Caruso, Hermioni L. Amonoo, Stephanie J. Lee, Joseph A. Greer, Jennifer S. Temel, Areej El-JawahriJournal of Clinical Oncology, Ahead of Print.
-
Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase–Targeted Approaches J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Toby A. Eyre, Chan Y. Cheah, Clémentine Sarkozy, Anita Kumar, Steven Le GouillJournal of Clinical Oncology, Ahead of Print.
-
Long-Term Dynamic Financial Impacts Among Adolescents and Young Adults With Cancer: A Longitudinal Matched-Cohort Study J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Giancarlo Di Giuseppe, Arif Jetha, Petros Pechlivanoglou, Jason D. PoleJournal of Clinical Oncology, Ahead of Print.
-
Results of combined therapy with pemetrexed and carboplatin in progressive ovarian cancer. J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Shakhnoza Niyozova, Sergey Kamishov, Oleg Balenkov, Odiljon Kobilov, Mirzagaleb TillyashaykhovJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page e17598-e17598, June 2025.
-
The impact of lymphocyte count dynamics on the predictive value of tumor mutational burden (TMB) for immune checkpoint inhibitors (ICI) outcomes in patients (pts) with cancer. J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Eddy Saad, Marc Machaalani, Razane El Hajj Chehade, Wassim Daoud Khatoun, Jad El Masri, Marc Eid, Rashad Nawfal, Karl Semaan, Emre Yekeduz, Clara Steiner, Liliana Ascione, Chris Labaki, Renee Maria Saliby, Talal El Zarif, Alexander Gusev, Toni K. ChoueiriJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page 2663-2663, June 2025.
-
Phase Ib/II study of fluzoparib in combination with dalpiciclib in patients with locally advanced or metastatic sarcoma. J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Jinchang Lu, Tianqi Luo, Jin WangJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page 11533-11533, June 2025.
-
Assessment of smartwatch-based electrocardiogram (ECG) abnormality detection among childhood cancer survivors. J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Ibrahim Karabayir, Luke Patterson, Stephanie B. Dixon, Daniel A. Mulrooney, Matthew Kalscheur, Tina Baykaner, Kirsten K. Ness, Melissa M. HudsonJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page 10069-10069, June 2025.
-
A phase II randomised study to evaluate the antitumour activity of roginolisib, a novel non-ATP competitive and allosteric modulator inhibiting PI3Kδ, in patients with metastatic uveal melanoma (OCULE-01). J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Anna Maria Di Giacomo, Josep M. Piulats, Giusy Di Conza, Tracey Hammett, Paramjit Kaur, Karen Tonge, Lars Anders van der Veen, Michael M. F. LahnJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS9613-TPS9613, June 2025.
-
Trial in progress: A phase 3 randomized study of low-dose intralesional cemiplimab versus primary surgery for patients with early-stage cutaneous squamous cell carcinoma (CLEAR CSCC). J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Sherrif Ibrahim, John Strasswimmer, Nathalie Zeitouni, Suk-Young Yoo, Frank A. Seebach, Israel Lowy, Mihaela C. Cristea, Matthew G. FuryJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS9612-TPS9612, June 2025.
-
A phase Ib study to assess the safety and efficacy of autologous tumor infiltrating lymphocytes (lifileucel) with adjuvant pembrolizumab (PEMBRO) for treatment of immunotherapy naïve patients with high-risk clinical stage IIIb-d resectable melanoma (MEL). J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Lucy Boyce Kennedy, Anthony P. Tufaro, Mark D. DeLacure, Anthony Visioni, Eren Berber, Daniel Raymond, Paolo Fabrizio Caimi, John C. Molina, Yee Peng Phoon, Joshua Arbesman, Jennifer S. Ko, Jan Joseph Melenhorst, Joseph J. Skitzki, Craig Steven Sauter, Brian Gastman, Thach-Giao TruongJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS9611-TPS9611, June 2025.
-
A phase 2 study to determine the clinical and pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in stage II to IV (M0) resectable cutaneous squamous cell carcinoma (Neo-SCC). J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Alexander Christopher Jonathan van Akkooi, Thomas Bennett, Sydney Ch'ng, Kerwin Frank Shannon, Michael Alexander Rtshiladze, Richard A. Scolyer, Robert V. Rawson, Monica Osorio, Rony Kapoor, Edward Hsiao, Helen Rizos, Serigne N. Lo, Alexander M. Menzies, Angela M. Hong, Georgina V. Long, Ines Esteves Domingues Pires da SilvaJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS9610-TPS9610, June 2025.
-
NEOSENT: Neoadjuvant anti-PD-1 therapy for patients with high-risk clinical stage II melanoma with a scheduled sentinel lymph node biopsy. J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Matheus Lobo, Andre Molina, Ivan Santos Filho, Manoel Coelho, Monique Celeste Tavares, Joao Paulo S. N. Lima, Rafaela Brito De Paula, Clovis Pinto, João Pedreira Duprat NetoJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS9609-TPS9609, June 2025.
-
Lymph node excision (LNEx) for patients with stage III melanoma with one clinically positive node: Excision of Lymph Node trial (EXCILYNT). J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Hong Zhu, Michael Lowe, Giorgos Constantine Karakousis, Lynn Thacher Dengel, Jay Soong-Jin Lee, Edmund Bartlett, Christina Vadala Angeles, Elizabeth Mary Gaughan, Georgia Beasley, Julia Terhune, Jie Deng, Roger Anderson, Terence Z. Wong, Kim BullockJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS9608-TPS9608, June 2025.
-
A phase 1/2 study of vusolimogene oderparepvec (RP1) in primary melanoma (mel) to reduce the risk of sentinel lymph node (SLN) metastasis. J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Jabra Zarka, Hong Wang, Yan Zang, Amy Rose, John M. Kirkwood, Jason J. Luke, Hassane M. Zarour, Diwakar Davar, Yana G. NajjarJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS9607-TPS9607, June 2025.
-
Neoadjuvant cemiplimab in cutaneous basal cell carcinoma of the head and neck. J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Hannah Kenny, Alban Linnenbach, Madalina Tuluc, Stacey Gargano, Scott W. Keith, Rita Susan Axelrod, Voichita Bar-Ad, Arielle Thal, Richard A. Goldman, David Cognetti, Adam J. Luginbuhl, Michael Topf, Michael Rabinowitz, Donald Weed, Wenyin Shi, Sara E. Lally, Carol L. Shields, Jennifer Maria Johnson, Joseph M. CurryJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS9606-TPS9606, June 2025.
-
A phase II study of binimetinib plus imatinib in patients with unresectable KIT-mutant melanoma. J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Gregory A. Daniels, Marjan Rajabi, Nicholas Lee, Adil Daud, Iwei YehJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS9605-TPS9605, June 2025.
-
TeLuRide-006: An adaptive phase 2/3 study of EIK1001, a Toll-like receptor 7/8 (TLR7/8) agonist, in combination with pembrolizumab in patients with advanced melanoma. J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Stéphane Dalle, Yin Wu, Oliver Edgar Bechter, Daniel Brungs, Anna Maria Di Giacomo, Hanna Eriksson, Peter Mohr, Rossanna C. Pezo, Egle Ramelyte, Bernardo Leon Rapoport, Gareth Rivalland, Amitesh Chandra Roy, Mizuho Fukunaga-Kalabis, Geetha Krishna Kaza, Yayan Zhang, Etah Kurland, Alexander M. EggermontJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS9604-TPS9604, June 2025.
-
Multicenter, randomized, double-blinded, placebo-controlled trial of IFx-Hu2.0 (IFx) as adjunctive therapy with pembrolizumab (pembro) in checkpoint inhibitor (CPI)-naïve patients with advanced or metastatic Merkel cell carcinoma (MCC). J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Melissa Amber Burgess, Gino Kim In, Karam Khaddour, Peter M O'Neill, Sunil A. Reddy, Eric D. Whitman, James A. BiancoJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS9603-TPS9603, June 2025.
-
Phase I dose escalation and expansion study of PRAME T-cell receptor (TCR) engineered IL15-transduced cord blood–derived natural killer (NK) cells in patients with recurrent and/or refractory melanoma (PRAMETIME-Mel). J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Reham Abdel-Wahab, Ruitao Lin, May Daher, Bin Liu, Rafet Basar, Elizabeth J. Shpall, Katy Rezvani, Adi DiabJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS9602-TPS9602, June 2025.
-
The TIME trial: Phase II randomized controlled trial of time-of-day–specified immunotherapy for advanced melanoma. J. Clin. Oncol. (IF 42.1) Pub Date : 2025
David C. Qian, Jeffrey Switchenko, Melinda Lynne Yushak, David H. Lawson, Michael LoweJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS9601-TPS9601, June 2025.
-
A phase 1, open-label, dose expansion cohort of the tolerability of tolododekin alfa (ANK-101) in combination with cemiplimab in cutaneous squamous cell carcinoma. J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Marcus O. Butler, Brendan D. Curti, Gail Iodice, Danielle M. Pastor, Joseph Elassal, Howard L. Kaufman, John M. KirkwoodJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS9600-TPS9600, June 2025.
-
A randomized, controlled, multicenter, phase 3 study of vusolimogene oderparepvec combined with nivolumab vs treatment of physician’s choice in patients with advanced melanoma that has progressed on anti–PD-1 and anti–CTLA-4 therapy (IGNYTE-3). J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Ardy Davarifar, Yana G. Najjar, Omid Hamid, Dirk Schadendorf, Michael K.K. Wong, Nikhil I. Khushalani, Paolo Antonio Ascierto, Tawnya Lynn Bowles, Mark Navarro, Giuseppe Gullo, Caroline RobertJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS9599-TPS9599, June 2025.
-
The MATRiX trial: A multicenter, randomized, phase II study of ATR inhibition (via tuvusertib) with or without avelumab in patients with advanced anti-PD-(L)1–refractory Merkel cell carcinoma. J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Evan Thomas Hall, George Ansstas, Shailender Bhatia, Andrew Scott Brohl, Melissa Amber Burgess, Maya Dimitrova, Ling Gao, Jeffrey Joseph Ishizuka, Evan J. Lipson, Jose Lutzky, Ann W. Silk, Jina Yun, Isaac Brownell, Judy Murray, Yvonne Marie Mowery, Ted Gooley, Steven Gore, Suzanne Louise Topalian, Paul NghiemJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS9598-TPS9598, June 2025.
-
A randomized, phase 2/3 clinical trial investigating RP2 plus nivolumab vs ipilimumab plus nivolumab in immune checkpoint inhibitor-naïve patients with metastatic uveal melanoma. J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Joseph J Sacco, Justin C. Moser, Allison Betof Warner, Ryan J. Sullivan, Diwakar Davar, Alexander Noor Shoushtari, Richard D. Carvajal, Sapna Pradyuman Patel, Anthony M. Joshua, Jessica Cecile Hassel, Mark Navarro, Rahul Marpadga, Giuseppe GulloJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS9597-TPS9597, June 2025.
-
A randomized phase 2 peri-operative (neoadjuvant plus adjuvant) study of fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) versus anti–PD-1 alone in patients with resectable stage III and IV melanoma. J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Axel Hauschild, Michael Lowe, Janis M. Taube, Adil Daud, Thach-Giao Truong, Sarah A. Weiss, Ankit Mangla, Tapan Miyani, Deidre Williams, Fang Fang, Shuquan Chen, Mark Salvati, Israel Lowy, Rossella Marullo, Matthew G. Fury, Karl Lewis, Humberto Lara-GuerraJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS9596-TPS9596, June 2025.
-
NivoReach: Integrated study to demonstrate similarity of JPB898 to reference nivolumab in combination with ipilimumab in patients with advanced melanoma. J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Journal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS9595-TPS9595, June 2025.
-
A multicenter, randomized, controlled, open-label, phase 2 study of the PD-1/IL-2α-bias bispecific antibody fusion protein IBI363 in mucosal and acral melanoma. J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Yu Chen, Zhiguo Luo, Xiaoshi Zhang, Di Wu, Ke Li, Zhengyun Zou, Meiyu Fang, Chen Jing, Huijing Feng, Yu Jiang, Weizhen Zhang, Xianan Li, Renbing Jiang, Enwen Wang, Cuihua Yi, Yinbin Zhang, Xueying Zhang, Xiubao Ren, Jun GuoJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS9594-TPS9594, June 2025.
-
Phase I/IIa dose finding study of triplet regimen of relatlimab (RELA), ipilimumab (IPI), and nivolumab (NIVO) in first-line therapy of metastatic melanoma (TRINITY). J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Tara Marie Davidson, Krysta McVay, Denai R. Milton, Rodabe Navroze Amaria, Isabella Claudia Glitza, Jennifer Leigh McQuade, Theresa H. Nguyen, Alexandra Ikeguchi, Adi Diab, Weiyi Peng, Michael A. Davies, Hussein A. TawbiJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS9593-TPS9593, June 2025.
-
Phase I/Ib study of concurrent intravenous (IV) and intrathecal (IT) nivolumab (N) and relatlimab (R) for metastatic melanoma (MM) patients (pts) with leptomeningeal disease (LMD). J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Suzanne Phillips, Ida John, Roland L. Bassett, Michelle L. Rohlfs, Jessie Richard, Masood Iqbal, Ian E. McCutcheon, Sherise D. Ferguson, Jeffrey S. Weinberg, Golnaz Morad, Adi Diab, Rodabe Navroze Amaria, Jennifer Leigh McQuade, Alexandra Ikeguchi, Hussein A. Tawbi, Elizabeth M. Burton, Michael A. DaviesJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS9592-TPS9592, June 2025.
-
Evaluating the use of educational videos in a medical oncology sarcoma clinic to improve patient knowledge and satisfaction. J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Jasjeet Kaur Matharu, Mona Domlog, Karen Lawrie, Abdulazeez Salawu, Abha A. Gupta, Yangqing Deng, Lisa Avery, Meaghen McDonald, Harleen Toor, Janet Papadakos, Albiruni Ryan Abdul Razak, Geoffrey Alan WatsonJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS9047-TPS9047, June 2025.
-
A randomized controlled trial of high-fidelity simulation versus mentoring training for residents: ACACIAS 2. J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Teeva Facchini-Joguet, Mickael Schaeffer, Sandra Pinet, Margaux Leoment, Emmanuel Gyan, Mathilde Cancel, Lobna Ouldamer, Vahan Kepenekian, Lise Lecointre, Didier Mutter, Philippe Trensz, Anne Patsouris, Raphael Olivier, Camille EvrardJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS9046-TPS9046, June 2025.
-
A global phase 2/3, randomized, open-label trial of BNT327/PM8002 in combination with chemotherapy (chemo) in first-line (1L) non-small cell lung cancer (NSCLC). J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Stephen V. Liu, Vinod Ganju, Suzanne Kosmider, Se-Hoon Lee, Mehmet Ali Nahit Sendur, Yvonne J. Summers, Nicolas Girard, Yotsawaj Runglodvatana, Hasna Bouchaab, Ilhan Celik, Ulug Mutlu Gunaydin, René Bartz, Sarita Koride, Li Li, Claudia-Nanette Gann, Ugur Sahin, Özlem Türeci, Shun LuJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS8670-TPS8670, June 2025.
-
A biomarker-directed, multi-center phase II/III study of ctDNA molecular response adaptive immuno-chemotherapy in patients with non-small cell lung cancer (BR.36). J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Sara Moore, Penelope Ann Bradbury, Cheryl Ho, Rosalyn A. Juergens, Adrian G. Sacher, Sofia Genta, Lacey Pitre, Michela Febbraro, Julie R. Brahmer, Egor Avrutin, Pierre-Olivier Gaudreau, Mark Sausen, Samik Upadhaya, Alicia Zhou, Keyue Ding, Janet Ellen DanceyJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS8669-TPS8669, June 2025.
-
TACTI-004: A double-blinded, randomized phase 3 trial in patients with advanced/metastatic non-small cell lung cancer receiving eftilagimod alfa (MHC class II agonist) in combination with pembrolizumab (P) and chemotherapy (C) versus placebo + P + C. J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Margarita Majem, Kenneth John O'Byrne, Thorsten Oliver Goetze, Christian Mueller, Frederic TriebelJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS8668-TPS8668, June 2025.
-
A phase 2 safety and efficacy study of PRT3789 in combination with pembrolizumab in patients with advanced or metastatic solid tumors and a SMARCA4 mutation. J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Martin Gutierrez, Wade Thomas Iams, Victor Moreno, Tatiana Hernandez Guerrero, Guzman Alonso, Carlos A. Gomez-Roca, Sophie Postel-Vinay, Fabian Acker, Anna Rachel Minchom, Natasha B. Leighl, William F. Novotny, Chris Tankersley, Megan Henry, Sunhee Ro, Michael Jon Chisamore, John BridgewaterJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS8667-TPS8667, June 2025.
-
Neladalkib (NVL-655), a highly selective anaplastic lymphoma kinase (ALK) inhibitor, compared to alectinib in first-line treatment of patients with ALK-positive advanced non-small cell lung cancer: The phase 3 ALKAZAR study. J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Benjamin J. Solomon, Tom Stinchcombe, Geoffrey Liu, Gilberto Lopes, Melissa Lynne Johnson, Misako Nagasaka, Ece Cali Daylan, Christina S. Baik, James Thomas D'Olimpio, Tzu-chuan Jane Huang, Alexander I. Spira, Daniel Ernest Haggstrom, Ben C. Creelan, Kristina Kehrig, Junwu Shen, Rachel DeLaRosa, Viola Weijia Zhu, Alexander E. Drilon, Alice Tsang ShawJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS8666-TPS8666, June 2025.
-
NVL-330, a selective HER2 tyrosine kinase inhibitor, in patients with advanced or metastatic HER2-altered non-small cell lung cancer: The phase 1 HEROEX-1 study. J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Zofia Piotrowska, Alexander I. Spira, Christina S. Baik, Maria Quintos Baggstrom, Gerald Steven Falchook, Joel W. Neal, Shirish M. Gadgeel, Gilberto Lopes, Melissa Lynne Johnson, Jonathan W. Riess, Danny Nguyen, Lisa Morelli, Danieska Sandino, Steven Margossian, Vivek Upadhyay, Fernando SantiniJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS8665-TPS8665, June 2025.
-
A randomized phase 3 study of ivonescimab plus chemotherapy versus pembrolizumab plus chemotherapy for the first-line treatment of metastatic non–small cell lung cancer: HARMONi-3. J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Jun Cai, Hui Wang, Yan Yu, Joaquim Bosch-Barrera, Reyes Bernabé, Zoran Andric, Firas Benyamine Badin, Yusuke Okuma, Paul K. Paik, Jarushka Naidoo, Haralabos Kalofonos, Bo Wang, Robert M. Jotte, Nathan A. Pennell, Jonathan W. Riess, Deborah Blythe Doroshow, Makoto Nishio, Jorge Arturo Alatorre-Alexander, Shun LuJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS8664-TPS8664, June 2025.
-
A phase 1/2 open-label, multicenter, first-in-human study of the safety, tolerability, pharmacokinetics, and antitumor activity of BH-30643 in adult subjects with locally advanced or metastatic NSCLC harboring EGFR and/or HER2 mutations (SOLARA). J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Alexander I. Spira, Melissa Lynne Johnson, Misako Nagasaka, Alexander Philipovskiy, Jyoti D. Patel, Sarah W. Gordon, Jonathan W. Riess, Lyudmila Bazhenova, Sonam Puri, Hidehito Horinouchi, Hiroki Izumi, Molly SC Li, Tom John, Sagun Parakh, Armin Graber, Geoff Oxnard, J. Jean Cui, Pingkuan Zhang, James Chih-Hsin YangJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS8663-TPS8663, June 2025.
-
Phase 2 cohort-2 trial in progress: Vabametkib plus lazertinib for patients with EGFR-mutant NSCLC who developed resistance to 1st-line, 3rd-gen-EGFR TKIs via C-Met dysregulation. J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Hye Ryun Kim, Hanlim Moon, Inyoung Kim, Nirmal Rajasekaran, Sunyhe Im, Na Young Kim, Jun Young Choi, Youngkee Shin, Se-Hoon LeeJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS8662-TPS8662, June 2025.
-
A multicenter, open-label, single-arm phase I/II study to assess the efficacy and safety of WSD0922-FU in patients with EGFR C797Sm+ advanced non-small cell lung cancer (NSCLC) in China (NCT06631989). J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Lily Liu, Carina Yu, Zhongyuan YangJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS8661-TPS8661, June 2025.
-
NAPISTAR 1-01: An international phase I/II trial of the novel ADC TUB-040 in platinum-resistant ovarian cancer (PROC) and relapsed/refractory adenocarcinoma non-small cell lung cancer (NSCLC). J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Antonio Gonzalez Martin, Shiraj Sen, Jalid Sehouli, Alex Spira, Valentina Boni, Rebecca Kristeleit, Debra L. Richardson, James F. Spicer, Juergen Wolf, Heather Scharpenseel, Lea Ruge, Frederik Herzberg, Ignacio Matos, Günter Fingerle-Rowson, Ines Isabel Monteiro Vasconcelos, Sebastian Ochsenreither, Alexander StarodubJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS8660-TPS8660, June 2025.
-
Phase 2, multicenter study of frontline maintenance therapy with lifileucel plus pembrolizumab in advanced non-small cell lung cancer. J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Scott N. Gettinger, Jason Alan Chesney, Ammar Sukari, Kai He, Sylvia Lee, Edward B. Garon, Jorge J. Nieva, Juan Martin-Liberal, Juan Francisco Rodriguez Moreno, Jon Zugazagoitia, Bernard Doger Doger de Spéville, Debra Hannah Josephs, Geoffrey Thomas Gibney, Sajeve Samuel Thomas, Yazan Samhouri, Selda Samakoglu, Minjie Feng, Friedrich Graf Finckenstein, Adam Jacob SchoenfeldJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS8659-TPS8659, June 2025.
-
TeliMET NSCLC-04: A phase 2, open-label, randomized, global study of 2 telisotuzumab vedotin regimens in patients with previously treated c-Met protein–overexpressing, locally advanced/metastatic non-squamous EGFR wildtype non-small cell lung cancer. J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Christine Ratajczak, Hephzibah Adamu, Shilpen Patel, Zhuangzhuang Liu, Summer Xia, Nancy ZhangJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS8658-TPS8658, June 2025.
-
FIRST-NEC (GFPC 01-2022): A multicenter phase II study evaluating the efficacy and safety of the combination of durvalumab with etoposide and platinum as first line treatment in patients with advanced large-cell neuroendocrine lung carcinomas (LCNECs). J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Dominique Arpin, Julien Gautier, Audrey Mansuet-Lupo, Aymeric De Monfort, Sylvie Chabaud, Chantal Decroisette Phan Van Ho, Sébastien Couraud, Marie Wislez, Simonneau Yannick, Solene Chaleat, Charles Ricordel, Anne Claire Toffart, Didier Debieuvre, Ivana Sondarjee, Jean-Bernard Auliac, Diane Damotte, Laurent Greillier, David Pérol, Luc OdierJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS8657-TPS8657, June 2025.
-
Krascendo 2: A phase III study of divarasib and pembrolizumab vs pembrolizumab and chemotherapy in patients with previously untreated, advanced or metastatic, KRAS G12C-mutated non-small cell lung cancer (NSCLC). J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Benjamin J. Solomon, Nikolaj S. Willy Frost, Rebecca Heist, Caicun Zhou, Martina Zarak Crnkovic, Vladan Antic, Hen Prizant, Mariah Clarisse Mayo, Christoph Meyenberg, Sophie Keufer-Le Gall, Sanjay PopatJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS8656-TPS8656, June 2025.
-
Phase 1b/2 study evaluating telisotuzumab adizutecan (ABBV-400; Temab-A) in combination with budigalimab in patients (pts) with advanced non-squamous (NSQ) non-small cell lung cancer (NSCLC) with no prior treatment for advanced disease and no actionable genomic alterations. J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Nicolas Girard, Shun Lu, Shirish M. Gadgeel, Kristof Cuppens, Se-Hoon Lee, Hidehito Horinouchi, Tae Min Kim, Angelo Delmonte, Elvire Pons-Tostivint, Robert M. Jotte, Nivedita Aanur, Han Coburn, Qi Jiang, Theodore S. Jennaro, Tony Navas, Yan Li, Jonathan W. GoldmanJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS8655-TPS8655, June 2025.
-
ARTEMIDE-Lung03: A phase 3, randomized, double-blind, multicenter, global study of rilvegostomig or pembrolizumab in combination with platinum-based chemotherapy as first-line treatment for patients with metastatic non-squamous non-small-cell lung cancer whose tumors express PD-L1. J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Yasushi Goto, Carolin Gross-Ophoff-Mueller, Shun Lu, Delvys Rodriguez-Abreu, Alona Zer, Moritz Wolfgang Drachsler, Maozhen Gong, James Hurlock, Jakub Tyszecki, Byoung Chul ChoJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS8653-TPS8653, June 2025.
-
KEYMAKER-U01 substudy 01A: Phase 1/2 study of pembrolizumab plus ifinatamab deruxtecan (I-DXd) or patritumab deruxtecan (HER3-DXd) with or without chemotherapy in untreated stage IV non–small-cell lung cancer. J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Tibor Csőszi, Zsuzsanna Szalai, Jair Bar, Nir Peled, Byoung Chul Cho, Yu Jung Kim, Dariusz M. Kowalski, Ernest Nadal, Jiaxin Niu, Justin F. Gainor, David Paul Carbone, Konstantin H. Dragnev, Kevin Chen, David W. Sternberg, Bin Zhao, Heng Zhou, Azadeh Namakydoust, Vamsidhar VelchetiJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS8652-TPS8652, June 2025.
-
Phase 3 trial of the therapeutic cancer vaccine OSE2101 versus docetaxel in patients with metastatic non-small cell lung cancer and secondary resistance to immunotherapy. J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Cyril Guibert, Elvire Pons Tostivint, Raffaele Califano, Ludovic Doucet, Thomas Egenod, Rafal Dziadziuszko, Santiago Viteri Ramirez, Federico Cappuzzo, Silvia Comis, Caroline Chevalier, Valerie Gabarre, Thomas Vandewalle, François Montestruc, Berangere Vasseur, Jordi Remon Masip, Benjamin BesseJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS8651-TPS8651, June 2025.
-
Phase 1/2 clinical trial of JIN-A02, a 4th generation EGFR-TKI in EGFR-mutated advanced/metastatic non-small cell lung cancer. J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Byoung Chul Cho, Ji-Youn Han, Sang-We Kim, Ki Hyeong Lee, Byoung Yong Shim, Jong-Mu Sun, Misako Nagasaka, Anna Jo, Ethan Seah, Choonok Kim, Thanyanan ReungwetwattanaJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS8650-TPS8650, June 2025.
-
Onkoras-101: A phase 1a/1b open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of BBO-8520 in subjects with advanced KRASG12C mutant non-small-cell lung cancer. J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Wallace L. Akerley, Vinod Ganju, Jun Zhang, Alex Adjei, Melissa Lynne Johnson, Alexander I. Spira, Lei Deng, Edward B. Garon, So Yeon Kim, Richard Frank, Lyudmila Bazhenova, Rasha Cosman, Rachel Roberts-Thomson, Christos Karapetis, Yong Ben, Foster GonsalvesJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS8649-TPS8649, June 2025.
-
SOHO-02: Phase III trial of BAY 2927088 in patients with locally advanced or metastatic NSCLC with HER2-activating mutations. J. Clin. Oncol. (IF 42.1) Pub Date : 2025
Koichi Goto, Shun Lu, Jan Christoph Brase, Judith Xu, Su-Fen Pu, Izabela Przybytniak, Lidia Mongay Soler, Edward B. Garon, Antonio PassaroJournal of Clinical Oncology, Volume 43, Issue 16_suppl, Page TPS8648-TPS8648, June 2025.
Copyright © 2014-2025 北京衮雪科技有限公司 All Rights Reserved
京ICP备11026495号-2
京公网安备 11010802027423号
京公网安备 11010802027423号